Skip to main content
OpenTrials
Completed

NCT Number: NCT02449941

Helicobacter Pylori and Proton Pump Inhibitor

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Helicobacter Infections Bacterial Infections Bacterial Infections and Mycoses Digestive System Diseases Digestive System Neoplasms Gastritis Gastritis, Atrophic Gastroenteritis Gastrointestinal Diseases Gastrointestinal Neoplasms Gram-Negative Bacterial Infections Infections Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Asan Medical Center

Seoul, Songpa-gu, 138-736, South Korea

About this study

Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are indicated to endoscopic resection due to gastric neoplasm
  • Aged between 19 to 65 years
  • Informed consent

Exclusion criteria

  • Previous history of HP eradication
  • Previous history of PPI use within 6 months
  • No HP infection

Treatment and study plan

PPI (proton pump inhibitor)

Drug
  • Pre ESD (endoscopic submucosal dissection)
  • Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
  • Use of PPI for 2 months
  • Post ESD 1 (After 2 months)
  • Assess the distribution of helicobacter pylori after using PPI.
  • Stop of PPI
  • Post ESD 2 (After 4 months)
  • Assess the distribution of helicobacter pylori after stop of PPI.

Other names: pantoprazole, lansoprazole, dexlansoprazole, rabeprazole

Primary outcomes

  1. Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor

    Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Secondary outcomes

  1. Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach

    Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Registry information

Official study title

Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 21, 2015
Registry last updated
Dec 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.